Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE issues final guidance for Servier's Protelos and BMS/Otsuka's Abilify

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal body for England and Wales, has issued two pieces of final guidance both of which confirmed the final draft guidance issued in December: on Bristol-Myers Squibb/Otsuka Pharmaceuticals' Abilify (aripiprazole), for treating young people with schizophrenia, and on Servier's Protelos (strontium ranelate) for preventing osteoporotic fractures.

You may also be interested in...



German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Cost Offsets Crucial For Uptake Of Advanced Therapies

To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel